COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery

[1]  M. Ghosh,et al.  Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients , 2022, Genes & diseases.

[2]  M. Ghosh,et al.  Chaperone-assisted E3 ligase CHIP: A double agent in cancer , 2021, Genes & diseases.

[3]  Jianqing Xu,et al.  Monitoring Coronavirus Disease 2019: A Review of Available Diagnostic Tools , 2021, Frontiers in Public Health.

[4]  G. Esmat,et al.  Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study , 2021, Journal of medical virology.

[5]  M. S. Rezai,et al.  Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial , 2021, Clinical Therapeutics.

[6]  Carolina Q. Sacramento,et al.  In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19 , 2021, The Journal of antimicrobial chemotherapy.

[7]  P. Taylor,et al.  Neutralizing monoclonal antibodies for treatment of COVID-19 , 2021, Nature Reviews Immunology.

[8]  K. Skorecki,et al.  The Double Edge Sword of Testosterone’s Role in the COVID-19 Pandemic , 2021, Frontiers in Endocrinology.

[9]  Andy Charlwood,et al.  HRM and the COVID‐19 pandemic: How can we stop making a bad situation worse? , 2021, Human Resource Management Journal.

[10]  B. Medhi,et al.  Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 , 2021, Annals of Internal Medicine.

[11]  F. Vidal,et al.  Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH) , 2021, Expert opinion on pharmacotherapy.

[12]  D. Barford,et al.  Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP , 2021, Proceedings of the National Academy of Sciences.

[13]  D. Skovronsky,et al.  Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[14]  D. Tegunov,et al.  Mechanism of SARS-CoV-2 polymerase stalling by remdesivir , 2021, Nature communications.

[15]  A. Elfiky,et al.  The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico , 2021, Molecular Diversity.

[16]  I. Al-Zakwani,et al.  Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia , 2020, International Journal of Infectious Diseases.

[17]  S. Joshi,et al.  Role of favipiravir in the treatment of COVID-19 , 2020, International Journal of Infectious Diseases.

[18]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[19]  R. Porcher,et al.  Remdesivir for COVID-19 in Europe: will it provide value for money? , 2020, The Lancet Respiratory Medicine.

[20]  H. Keyvani,et al.  Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial , 2020, BMC Infectious Diseases.

[21]  A. A. Onischuk,et al.  Aerosol Inhalation Delivery of Triazavirin in Mice: Outlooks for Advanced Therapy Against Novel Viral Infections , 2020, Journal of Pharmaceutical Sciences.

[22]  Jinzi J. Wu,et al.  First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients , 2020, Medicine.

[23]  V. Belousov,et al.  Practical Experience of Using Riamilovir in Treatment of Patients with Moderate COVID-19 , 2020 .

[24]  Daniel P. Walsh,et al.  Veno-venous extracorporeal membrane oxygenation allocation in the COVID-19 pandemic , 2020, Journal of Critical Care.

[25]  H. Ogawa,et al.  COVID-19-associated coagulopathy and disseminated intravascular coagulation , 2020, International Journal of Hematology.

[26]  R. Bauer,et al.  Antiviral activity of plant juices and green tea against SARS‐CoV‐2 and influenza virus , 2020, bioRxiv.

[27]  H. Ogawa,et al.  Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation , 2020, International Journal of Infectious Diseases.

[28]  D. Annane,et al.  Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study , 2020, EClinicalMedicine.

[29]  D. Skovronsky,et al.  SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 , 2020, The New England journal of medicine.

[30]  Shahalam Khan,et al.  Combating COVID-19: The role of drug repurposing and medicinal plants , 2020, Journal of Infection and Public Health.

[31]  N. Al-Dhabi,et al.  Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach , 2020, Journal of Infection and Public Health.

[32]  K. Sharun,et al.  Ebselen, a new candidate therapeutic against SARS-CoV-2 , 2020, International Journal of Surgery.

[33]  Samuel M. Galvagno,et al.  Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019 , 2020, Anesthesia and analgesia.

[34]  J. Qi,et al.  Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir , 2020, bioRxiv.

[35]  C. del Rio,et al.  Long-term Health Consequences of COVID-19. , 2020, JAMA.

[36]  A. Ryo,et al.  Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico , 2020, Microorganisms.

[37]  Jennifer L. Bell,et al.  Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2020, The Lancet.

[38]  G. Landoni,et al.  Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence- , 2020, International Journal of Cardiology.

[39]  C. Le Page,et al.  Repurposing anticancer drugs for the management of COVID-19 , 2020, European Journal of Cancer.

[40]  Liping Jiang,et al.  Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis , 2020, BMJ Supportive & Palliative Care.

[41]  C. Shanmugam,et al.  COVID-2019 – A comprehensive pathology insight , 2020, Pathology - Research and Practice.

[42]  B. Coutard,et al.  Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis , 2020, Nature Communications.

[43]  F. Frigieri,et al.  Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action , 2020, Thrombosis Research.

[44]  M. Zhang,et al.  Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial , 2020, Engineering.

[45]  R. Singh,et al.  Drug repurposing approach to fight COVID-19 , 2020, Pharmacological Reports.

[46]  Á. Avezum,et al.  Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. , 2020, JAMA.

[47]  Arthur S Slutsky,et al.  Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.

[48]  Z. Natto,et al.  A contemporary look at COVID-19 medications: available and potentially effective drugs. , 2020, European review for medical and pharmacological sciences.

[49]  L. Tang,et al.  Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19 , 2020, European journal of clinical pharmacology.

[50]  Yvette N. Lamb.  Remdesivir: First Approval , 2020, Drugs.

[51]  J. Shapiro,et al.  Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[52]  Q. de Mast,et al.  Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients , 2020, EBioMedicine.

[53]  O. Tsang,et al.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[54]  F. Drago,et al.  The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review , 2020, Frontiers in Pharmacology.

[55]  F. Saghafi,et al.  Pharmacological treatments of COVID-19 , 2020, Pharmacological Reports.

[56]  J. Eswari,et al.  Emerging strategies on in silico drug development against COVID-19: challenges and opportunities , 2020, European Journal of Pharmaceutical Sciences.

[57]  Z. Lotfi,et al.  The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19 , 2020, The Journal of antimicrobial chemotherapy.

[58]  A. Davarpanah,et al.  Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial , 2020, The Journal of antimicrobial chemotherapy.

[59]  S. Merat,et al.  Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial , 2020, The Journal of antimicrobial chemotherapy.

[60]  Vivek Gupta,et al.  Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges , 2020, Life Sciences.

[61]  S. Jockusch,et al.  Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir , 2020, Scientific Reports.

[62]  N. Savchuk,et al.  AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  E. Schenck,et al.  Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19 , 2020, Clinical Immunology.

[64]  T. Akahoshi,et al.  Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate , 2020, Journal of Infection and Chemotherapy.

[65]  S. M. Asdaq,et al.  Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review , 2020, Journal of Infection and Public Health.

[66]  M. Vargas,et al.  Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. , 2020, European review for medical and pharmacological sciences.

[67]  J. Hewitt,et al.  Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19 , 2020, Journal of clinical medicine.

[68]  D. Mallardo,et al.  Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy , 2020, Journal for ImmunoTherapy of Cancer.

[69]  A. Hussain,et al.  Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies , 2020, Biomedicine & Pharmacotherapy.

[70]  M. Veettil,et al.  Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection , 2020, European Journal of Pharmacology.

[71]  M. Bassetti,et al.  Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19” , 2020, Open forum infectious diseases.

[72]  F. Violi,et al.  Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ? , 2020, Drugs.

[73]  Zhihai Chen,et al.  Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients , 2020, Journal of acquired immune deficiency syndromes.

[74]  Oliver Schnell,et al.  Issues for the management of people with diabetes and COVID-19 in ICU , 2020, Cardiovascular Diabetology.

[75]  G. Paolisso,et al.  Covid-19 Kills More Men Than Women: An Overview of Possible Reasons , 2020, Frontiers in Cardiovascular Medicine.

[76]  F. Cadegiani,et al.  Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS) , 2020, Medical Hypotheses.

[77]  A. von Brunn,et al.  Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19 , 2020, Medicine in Drug Discovery.

[78]  Y. Muhammed.  Molecular targets for COVID-19 drug development: Enlightening Nigerians about the pandemic and future treatment , 2020, Biosafety and Health.

[79]  K. Miyazono,et al.  Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series , 2020, Critical Care.

[80]  J. Vinetz,et al.  Dexamethasone in the management of covid -19 , 2020, BMJ.

[81]  Christoph Nitsche,et al.  The SARS-CoV-2 main protease as drug target , 2020, Bioorganic & Medicinal Chemistry Letters.

[82]  A. Prakash,et al.  Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis , 2020, Indian journal of pharmacology.

[83]  Xiuhong Zhang,et al.  Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19 , 2020, International Immunopharmacology.

[84]  J. Wise.  Covid-19: Remdesivir is recommended for authorisation by European Medicines Agency , 2020, BMJ.

[85]  M. Parnham,et al.  Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections , 2020, Free Radical Biology and Medicine.

[86]  Mohammad Tariqur Rahman.  Potential benefits of combination of Nigella sativa and Zn supplements to treat COVID-19 , 2020, Journal of Herbal Medicine.

[87]  P. Lotti,et al.  Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study , 2020, The Journal of Infection.

[88]  A. A. Mutair,et al.  Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis , 2020, medRxiv.

[89]  H. Rahman,et al.  COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts , 2020, Le Pharmacien Hospitalier et Clinicien.

[90]  I. Youngster,et al.  Ibuprofen use and clinical outcomes in COVID-19 patients , 2020, Clinical Microbiology and Infection.

[91]  W. Ye,et al.  Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors , 2020, International Journal of Antimicrobial Agents.

[92]  J. Fraser,et al.  ECMO use in COVID-19: lessons from past respiratory virus outbreaks—a narrative review , 2020, Critical Care.

[93]  N. Mondaini.  Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management? , 2020, The world journal of men's health.

[94]  A. Fanin,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19 , 2020, Internal and Emergency Medicine.

[95]  A. Rodríguez-Morales,et al.  Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 , 2020, Annals of Clinical Microbiology and Antimicrobials.

[96]  P. Cecchini,et al.  COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients , 2020, Journal of medical virology.

[97]  Yanxia Huang,et al.  A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID‐19 , 2020, Journal of medical virology.

[98]  Zhiquan Hu,et al.  Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals , 2020, Frontiers in Public Health.

[99]  S. Ayis,et al.  The association between treatment with heparin and survival in patients with Covid-19 , 2020, Journal of Thrombosis and Thrombolysis.

[100]  W. Xu,et al.  Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases , 2020, International journal of molecular sciences.

[101]  Sumra Wajid Abbasi,et al.  Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment , 2020, Journal of biomolecular structure & dynamics.

[102]  G. Lemperle,et al.  Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? , 2020, Internal and Emergency Medicine.

[103]  Francia Carolina Acosta Saltos,et al.  Entry of SARS-CoV2 through the Basal Surface of Alveolar Endothelial Cells – A Proposed Mechanism Mediated by CD147 in COVID-19 , 2020 .

[104]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[105]  K. Naber,et al.  Thymoquinone: shield and sword against SARS-CoV-2 , 2020, Precision Nanomedicine.

[106]  Xilong Deng,et al.  Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial , 2020, Med.

[107]  K. Burgess,et al.  Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps , 2020, ACS medicinal chemistry letters.

[108]  A. Gasbarrini,et al.  Sarilumab use in severe SARS-CoV-2 pneumonia , 2020, EClinicalMedicine.

[109]  Ana Allende,et al.  SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area , 2020, Water Research.

[110]  B. Coutard,et al.  Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase , 2020, bioRxiv.

[111]  P. Marik,et al.  Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19 , 2020, Frontiers in Medicine.

[112]  Hongyu Zhao,et al.  Androgen Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men , 2020, bioRxiv.

[113]  Renyi Wu,et al.  An Update on Current Therapeutic Drugs Treating COVID-19 , 2020, Current Pharmacology Reports.

[114]  L. Amorosa,et al.  An Update on Current Therapeutic Drugs Treating COVID-19 , 2020, Current Pharmacology Reports.

[115]  H. Yanai.  Favipiravir: A Possible Pharmaceutical Treatment for COVID-19 , 2020 .

[116]  V. Fuster,et al.  Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[117]  I. Berindan‐Neagoe,et al.  Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2 , 2020, Pharmacological Research.

[118]  G. Racagni,et al.  NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators? , 2020, Pharmacological Research.

[119]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[120]  A. Elfiky,et al.  SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective , 2020, Journal of biomolecular structure & dynamics.

[121]  D. Havlir,et al.  Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19 , 2020, The New England journal of medicine.

[122]  Jerrine Joseph,et al.  Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach , 2020, Journal of biomolecular structure & dynamics.

[123]  Arun K. Ghosh,et al.  Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics , 2020, ChemMedChem.

[124]  Nils Kucher,et al.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.

[125]  E. Nicastri,et al.  Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact , 2020, Journal of Infection.

[126]  H. Ulrich,et al.  CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement , 2020, Stem Cell Reviews and Reports.

[127]  Nan Tang,et al.  SARS-CoV-2 and viral sepsis: observations and hypotheses , 2020, The Lancet.

[128]  Madeeha Kamal,et al.  Therapeutic management of patients with COVID-19: a systematic review , 2020, Infection Prevention in Practice.

[129]  Jie Li,et al.  Diagnosis and treatment of novel coronavirus pneumonia based on the theory of traditional Chinese medicine , 2020, Journal of Integrative Medicine.

[130]  S. Ünal,et al.  Antiviral treatment of COVID-19 , 2020, Turkish journal of medical sciences.

[131]  Joy Y. Feng,et al.  Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.

[132]  E. Decroly,et al.  Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites , 2020, Antiviral Research.

[133]  Yan Zhang,et al.  Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir , 2020, bioRxiv.

[134]  Bhumi M. Shah,et al.  In silico studies on therapeutic agents for COVID-19: Drug repurposing approach , 2020, Life Sciences.

[135]  Hualiang Jiang,et al.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.

[136]  W. Ageno,et al.  COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). , 2020, Blood transfusion = Trasfusione del sangue.

[137]  M. Corbellino,et al.  Baricitinib for COVID-19: a suitable treatment? – Authors' reply , 2020, The Lancet Infectious Diseases.

[138]  Xuhui Huang,et al.  Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro , 2020, Antiviral Research.

[139]  C. Montecucco,et al.  Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies , 2020, Annals of the Rheumatic Diseases.

[140]  I. Vlodavsky,et al.  The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID‐19 Patients: A Retrospective Cohort Study , 2020, Clinical and translational science.

[141]  Jiansheng Huang,et al.  Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 , 2020, Journal of clinical medicine.

[142]  Duanqing Pei,et al.  Treating COVID-19 with Chloroquine , 2020, Journal of molecular cell biology.

[143]  Agency European Medicines.  EMA advice on the use of NSAIDs for Covid-19 , 2020, Drug and Therapeutics Bulletin.

[144]  C. Delaugerre,et al.  No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection , 2020, Médecine et Maladies Infectieuses.

[145]  Sven Van Poucke,et al.  COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies , 2020, Journal of clinical and translational hepatology.

[146]  Y. Ho,et al.  SARS-CoV-2: A Storm is Raging. , 2020, The Journal of clinical investigation.

[147]  A. Elfiky,et al.  Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study , 2020, Life Sciences.

[148]  Ping Zhu,et al.  Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial , 2020, medRxiv.

[149]  Xilong Deng,et al.  An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI) , 2020, medRxiv.

[150]  Bo Chen,et al.  Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial , 2020, medRxiv.

[151]  France Mentré,et al.  A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19 , 2020, medRxiv.

[152]  D. Raoult,et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.

[153]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[154]  Wu Zhong,et al.  Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study , 2020, Engineering.

[155]  Z. Hong,et al.  Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study , 2020, Journal of Infection.

[156]  Jianjun Gao,et al.  Discovering drugs to treat coronavirus disease 2019 (COVID-19). , 2020, Drug discoveries & therapeutics.

[157]  Hongzhou Lu,et al.  [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. , 2020, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.

[158]  K. Nicolaides,et al.  Maternal cardiac function in women at high risk for pre‐eclampsia treated with 150 mg aspirin or placebo: an observational study , 2020, BJOG : an international journal of obstetrics and gynaecology.

[159]  D. Gurwitz.  Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics , 2020, Drug development research.

[160]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[161]  Suranga L Senanayake.  Drug repurposing strategies for COVID-19 , 2020, Future Drug Discovery.

[162]  Erin E. Mulvihill,et al.  Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism , 2020, Clinical medicine insights. Endocrinology and diabetes.

[163]  Mubarak A. Alamri,et al.  Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants , 2020, Journal of Pharmaceutical Analysis.

[164]  T. Pan,et al.  Teicoplanin potently blocks the cell entry of 2019-nCoV , 2020, medRxiv.

[165]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[166]  Gengfu Xiao,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[167]  Kai Zhao,et al.  Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[168]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[169]  Winnie Martinez,et al.  National Institute of Diabetes and Digestive and Kidney Diseases , 2020, Definitions.

[170]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[171]  M. Toumi,et al.  Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al , 2020, Journal of market access & health policy.

[172]  Shan Chang,et al.  The selenium-containing drug ebselen potently disrupts LEDGF/p75-HIV-1 integrase interaction by targeting LEDGF/p75 , 2020, Journal of enzyme inhibition and medicinal chemistry.

[173]  Naveen Vankadari,et al.  Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 , 2020, Emerging microbes & infections.

[174]  H. Naim,et al.  Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus , 2020, Emerging microbes & infections.

[175]  D. Webb,et al.  Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease , 2019, British journal of pharmacology.

[176]  M. Oyewumi,et al.  Delivery Systems as Vital Tools in Drug Repurposing , 2019, AAPS PharmSciTech.

[177]  Nermin S. Ahmed.  Tadalafil: 15 years' journey in male erectile dysfunction and beyond , 2018, Drug development research.

[178]  M. Lacouture,et al.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies , 2018, Breast Cancer Research and Treatment.

[179]  S. Dudek,et al.  DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. , 2018, American journal of physiology. Lung cellular and molecular physiology.

[180]  A. Tosti,et al.  Safety concerns when using novel medications to treat alopecia , 2018, Expert opinion on drug safety.

[181]  L. Ge,et al.  The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials , 2018, Acta Diabetologica.

[182]  S. Lyapustina.  Regulatory pitfalls and opportunities when repurposing for inhalation therapy. , 2018, Advanced drug delivery reviews.

[183]  S. Newman.  Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases. , 2018, Advanced drug delivery reviews.

[184]  Deric M. Park,et al.  Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy , 2018, Journal of Immunotherapy for Cancer.

[185]  L. Berrino,et al.  Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article , 2018, Inflammopharmacology.

[186]  W. Xie,et al.  Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension , 2018, Laboratory Investigation.

[187]  Peisheng Xu,et al.  Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly. , 2017, Acta biomaterialia.

[188]  E. Deeks.  Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection , 2016, Drugs.

[189]  G. Raghu.  Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential , 2017, European Respiratory Review.

[190]  Y. Furuta,et al.  Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase , 2017, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[191]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[192]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[193]  G. Sourvinos,et al.  Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARγ , 2017, Oncotarget.

[194]  N. Mikhailova,et al.  Effect of triazavirine on the outcome of a lethal influenza infection and secondary bacterial pneumonia following influenza in mice , 2017 .

[195]  L. Ganju,et al.  Broad-spectrum antiviral properties of andrographolide , 2017, Archives of Virology.

[196]  A. Sarma,et al.  Aspirin Use in Women: Current Perspectives and Future Directions , 2016, Current Atherosclerosis Reports.

[197]  R. Saito,et al.  Japanese Surveillance Systems and Treatment for Influenza , 2016, Current Treatment Options in Infectious Diseases.

[198]  D. Raoult,et al.  Fighting viruses with antibiotics: an overlooked path , 2016, International Journal of Antimicrobial Agents.

[199]  C. Klemann,et al.  Cut to the chase: a review of CD26/dipeptidyl peptidase‐4's (DPP4) entanglement in the immune system , 2016, Clinical and experimental immunology.

[200]  D. Talmor,et al.  Effect of Aspirin on Development of ARDS in At-Risk Patients Presenting to the Emergency Department: The LIPS-A Randomized Clinical Trial. , 2016, JAMA.

[201]  H. Jun,et al.  Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control , 2016, Mediators of inflammation.

[202]  T. Pan,et al.  Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) , 2016, The Journal of Biological Chemistry.

[203]  A. Bello,et al.  Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection , 2016, Antiviral Research.

[204]  W. Oh,et al.  Discovery of inhibitory materials against PEDV corona virus from medicinal plants , 2016 .

[205]  A. Lambeir,et al.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis , 2015, Front. Immunol..

[206]  Nina Wronkowitz,et al.  DPP4 in Diabetes , 2015, Front. Immunol..

[207]  G. Bernard,et al.  Prehospital Aspirin Use Is Associated With Reduced Risk of Acute Respiratory Distress Syndrome in Critically Ill Patients: A Propensity-Adjusted Analysis* , 2015, Critical care medicine.

[208]  Zhi Cai,et al.  Promising Anti-influenza Properties of Active Constituent of Withania somnifera Ayurvedic Herb in Targeting Neuraminidase of H1N1 Influenza: Computational Study , 2015, Cell Biochemistry and Biophysics.

[209]  O. Chupakhin,et al.  [Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice]. , 2015, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].

[210]  A. Lefor,et al.  Favipiravir: A New Medication for the Ebola Virus Disease Pandemic , 2014, Disaster Medicine and Public Health Preparedness.

[211]  C. K. Edwards,et al.  The Biological Function and Clinical Utilization of CD147 in Human Diseases: A Review of the Current Scientific Literature , 2014, International journal of molecular sciences.

[212]  Chad E. Schroeder,et al.  Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication , 2014, ACS chemical biology.

[213]  M. Timmers,et al.  Pharmacokinetics of darunavir in fixed‐dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers , 2014, Journal of clinical pharmacology.

[214]  Jeffrey J. Fong,et al.  Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection. , 2014, The Annals of pharmacotherapy.

[215]  T. van de Casteele,et al.  Bioequivalence of a Darunavir/Cobicistat Fixed-Dose Combination Tablet versus Single Agents and Food Effect in Healthy Volunteers , 2014, Antiviral therapy.

[216]  C. Stedman,et al.  Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential , 2014, Therapeutic advances in gastroenterology.

[217]  Bin Wang,et al.  Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. , 2014, Journal of medicinal chemistry.

[218]  Christian Drosten,et al.  Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS , 2013, Antiviral Research.

[219]  O. Chupakhin,et al.  [Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture]. , 2014, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].

[220]  E. Deeks.  Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection , 2014, Drugs.

[221]  Choongho Lee.  Daclatasvir: potential role in hepatitis C , 2013, Drug design, development and therapy.

[222]  G. Rossi,et al.  Melatonin: its possible role in the management of viral infections-a brief review , 2013, Italian Journal of Pediatrics.

[223]  K. Antoniou,et al.  Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future , 2013, European Respiratory Review.

[224]  Yue Wu,et al.  Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α‐reductase inhibitors , 2013, The Prostate.

[225]  Yi Shi,et al.  Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.

[226]  S. Iwata,et al.  Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-α in THP-1 Cells and Monocytes , 2013, PloS one.

[227]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[228]  Libin Rong,et al.  Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life , 2013, Proceedings of the National Academy of Sciences.

[229]  R. Bellomo,et al.  A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. , 2013, American journal of respiratory and critical care medicine.

[230]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[231]  W. Oh,et al.  Curcuminoids from Curcuma longa and their inhibitory activities on influenza A neuraminidases , 2012 .

[232]  Tudor I. Oprea,et al.  Drug Repurposing: Far Beyond New Targets for Old Drugs , 2012, The AAPS Journal.

[233]  S. Ha,et al.  Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes , 2012, Diabetologia.

[234]  C. Muller,et al.  EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. , 2012, Antiviral research.

[235]  Yong‐Joo Jeong,et al.  Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13 , 2012, Bioorganic & Medicinal Chemistry Letters.

[236]  D. Davis,et al.  Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against the Initial Autocleavage in Gag-Pol Polyprotein Processing , 2012, Antimicrobial Agents and Chemotherapy.

[237]  D. Harrich,et al.  Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus , 2012, The Biochemical journal.

[238]  H. Kato,et al.  Melatonin in bacterial and viral infections with focus on sepsis: a review. , 2012, Recent patents on endocrine, metabolic & immune drug discovery.

[239]  Tudor I. Oprea,et al.  Drug Repurposing from an Academic Perspective. , 2011, Drug discovery today. Therapeutic strategies.

[240]  I. Gonda,et al.  Formulation technology to repurpose drugs for inhalation delivery , 2011 .

[241]  D. Talmor,et al.  Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. , 2011, Chest.

[242]  M. Kukhanova,et al.  Antiviral Properties, Metabolism, and Pharmacokinetics of a Novel Azolo-1,2,4-Triazine-Derived Inhibitor of Influenza A and B Virus Replication , 2010, Antimicrobial Agents and Chemotherapy.

[243]  P. Nelson,et al.  Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. , 2010, Cancer research.

[244]  R. Purohit,et al.  Structural basis for the resilience of Darunavir (TMC114) resistance major flap mutations of HIV-1 protease , 2009, Interdisciplinary Sciences: Computational Life Sciences.

[245]  P. Sritara,et al.  Atorvastatin attenuates TLR4-mediated NF-kappaB activation in a MyD88-dependent pathway. , 2009, Asian Pacific journal of allergy and immunology.

[246]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[247]  V. A. Maksimov,et al.  [Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]. , 2007, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].

[248]  A. Chang,et al.  Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. , 2007, The Cochrane database of systematic reviews.

[249]  Dirk Jochmans,et al.  TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[250]  D. Diz,et al.  Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.

[251]  F. Calvo,et al.  Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. , 2005, The American journal of pathology.

[252]  G. Glenner,et al.  A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide , 2004, Histochemie.

[253]  M. Lai,et al.  Identification of a Ribavirin‐resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy , 2003, Hepatology.

[254]  L. Chiang,et al.  In vitro antiviral activities of Caesalpinia pulcherrima and its related flavonoids. , 2003, The Journal of antimicrobial chemotherapy.

[255]  J. Peiris,et al.  Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome , 2003, The Lancet.

[256]  Rolf Hilgenfeld,et al.  Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs , 2003, Science.

[257]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[258]  C. Durinx,et al.  Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV , 2003, Critical reviews in clinical laboratory sciences.

[259]  M. Belvisi,et al.  Differential Effects of Ebselen on Neutrophil Recruitment, Chemokine, and Inflammatory Mediator Expression in a Rat Model of Lipopolysaccharide-Induced Pulmonary Inflammation , 2002, The Journal of Immunology.

[260]  J. Eikelboom,et al.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2002, The New England journal of medicine.

[261]  K. Motomura,et al.  The selenoorganic compound ebselen suppresses liver injury induced by Propionibacterium acnes and lipopolysaccharide in rats. , 2001, International journal of molecular medicine.

[262]  K. Zilles,et al.  Ebselen lowers plasma interleukin-6 levels and glial heme oxygenase-1 expression after focal photothrombotic brain ischemia. , 2000, Archives of biochemistry and biophysics.

[263]  I. Goldstein,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, The New England journal of medicine.

[264]  J. Blay,et al.  Isolation and characterization of an anti-HSV polysaccharide from Prunella vulgaris. , 1999, Antiviral research.

[265]  Tom F. Lue,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.

[266]  Chika Morimoto,et al.  The structure and function of CD26 in the T‐cell immune response , 1998, Immunological reviews.

[267]  J. Grzybek,et al.  Antiviral activity of the infusion (SHS‐174) from flowers of Sambucus nigra L., aerial parts of Hypericum perforatum L., and roots of Saponaria officinalis L. against influenza and herpes simplex viruses , 1990 .